A study published in The EMBO Journal opens new perspectives to better understand how the molecular mechanisms involved in regenerative medicine work.
FDA approves Eisai and Biogen’s LEQEMBI sBLA for Alzheimer’s
The therapy is intended for individuals with mild cognitive impairment or mild dementia stage. Credit: Chinnapong/Shutterstock. The US Food and Drug Administration has approved the
January 27, 2025